Loading clinical trials...
Loading clinical trials...
Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapsed / Refractory Multiple Myeloma (MM)
Conditions
Interventions
P-BCMA-ALLO1 CAR-T cells
Rimiducid
+1 more
Locations
23
United States
City of Hope
Goodyear, Arizona, United States
University of California San Diego
San Diego, California, United States
University of California San Francisco
San Francisco, California, United States
Emory University
Atlanta, Georgia, United States
Blood Marrow and Transplant Group of Georgia
Atlanta, Georgia, United States
City of Hope
Chicago, Illinois, United States
Start Date
May 5, 2022
Primary Completion Date
March 1, 2029
Completion Date
March 1, 2042
Last Updated
April 24, 2026
NCT07249528
NCT06215118
NCT06679101
NCT05969860
NCT06383143
NCT06057402
Lead Sponsor
Poseida Therapeutics, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions